Rallis India Q3 - Inline Quarter: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Rallis India reported inline set of results driven by 19% growth in domestic business. Cropcare segment grew 5% (volume growth of 10%) driven by 15% growth in domestic business. International business dragged cropcare segment with 17% decline in realisations, due to sharp decline in Metribuzin price and drop in CRAMS business volumes. Ex-off metribuzin and PEKK, demand is resilient in international business.
Domestic business is on a strong footing in both crop protection and seeds with healthy demand, new launches (1 in CP, 2 in crop nutrition) and faster collection. Rallis has completed capex for 3 molecules in Q3, while other 2 molecules will be completed by April 21. The management also plans to invest Rs 1.2 billion in MPP, to be operationalised by H2 2022.
Management’s strategy of capacity expansion driven growth continues and we maintain our positive bias from a long term point of view.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.